Johnson & Johnson Joins Forces With Veracyte For Lung Cancer Diagnostics
Johnson & Johnson has entered a strategic collaboration with genomics diagnostics company Veracyte to develop and commercialize tests for detecting lung cancer.
You may also be interested in...
The 9,000-patient clinical study will identify genomic and other differences in lung cancer development and progression among patients with lung nodules detected by computed tomography.
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.